Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study

Sponsor
Shenzhen Raysight Intelligent Medical Technology Co., Ltd. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06039748
Collaborator
Renmin Hospital of Wuhan University (Other), Yan'an Affiliated Hospital of Kunming Medical University (Other), Sir Run Run Shaw Hospital (Other), The Eighth Affiliated Hospital of Sun Yat-sen University (Other), Jieyang People's Hospital (Other)
330
13.6

Study Details

Study Description

Brief Summary

Coronary angiography-derived FFR assessment (AngioQFA) is a novel technique for physiological lesion assessment based on 3-dimensional (3D) quantitative coronary angiography (QCA) and virtual hyperemic flow derived from contrast frame count without drug-induced hyperemia. The goal of this prospective, multicenter trial is to compare the diagnostic performance of AngioQFA with invasive FFR as the reference standard. The secondary purpose is to compare the diagnostic accuracies of the computational fluid dynamics (CFD)-based index of microcirculatory resistance (IMR) using wire-based IMR as the reference standard.

Study Design

Study Type:
Observational
Anticipated Enrollment :
330 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Performance of Angiography-Derived Quantitative Functional Assessment Compared to Pressure-Derived Fractional Flow Reserve and Index of Microcirculatory Resistance: The FAIR Study
Anticipated Study Start Date :
Sep 11, 2023
Anticipated Primary Completion Date :
Oct 30, 2024
Anticipated Study Completion Date :
Oct 30, 2024

Arms and Interventions

Arm Intervention/Treatment
AngioQFA

Other: AngioQFA
FFR measured by pressure wire, AngioQFA computed by coronary angiographic images

Outcome Measures

Primary Outcome Measures

  1. Diagnostic sensitivity of AngioQFA versus wire-based FFR for demonstration of coronary ischemia on a per-patient basis. [1 hour]

    Positive FFR is defined as FFR≤0.80. Positive AngioQFA is defined as AngioQFA≤0.80.

  2. Diagnostic sensitivity of AngioIMR versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-patient basis. [1 hour]

    Positive IMR is defined as IMR≥25. Positive AngioIMR is defined as AngioIMR≥25.

  3. Diagnostic specificity of AngioQFA versus wire-based FFR for demonstration of coronary ischemia on a per-patient basis. [1 hour]

    Negative FFR is defined as FFR>0.80. Negative AngioQFA is defined as AngioQFA>0.80.

  4. Diagnostic specificity of AngioIMR versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-patient basis. [1 hour]

    Negative IMR is defined as IMR<25. Negative AngioIMR is defined as AngioIMR<25.

Secondary Outcome Measures

  1. Diagnostic accuracy, positive predictive value and negative predictive value of AngioQFA versus wire-based FFR for demonstration of coronary ischemia on a per-patient basis. [1 hour]

    Diagnostic accuracy, positive predictive value and negative predictive value of AngioQFA versus wire-based FFR for demonstration of coronary ischemia on a per-patient basis.

  2. Diagnostic performance of AngioQFA in comparison to FFR on a per-vessel basis. [1 hour]

    Diagnostic performance includes sensitivity, specificity, accuracy, positive predictive value and negative predictive value.

  3. AUC and ROC of AngioQFA Versus wire-based FFR for demonstration of ischemia on a per-vessel basis and a per-patient basis. [1 hour]

    AUC and ROC of AngioQFA Versus wire-based FFR for demonstration of ischemia on a per-vessel basis and a per-patient basis.

  4. The consistency of AngioQFA Versus wire-based FFR for demonstration of ischemia on a per-vessel basis and a per-patient basis. [1 hour]

    The consistency of AngioQFA Versus wire-based FFR for demonstration of ischemia on a per-vessel basis and a per-patient basis.

  5. Diagnostic accuracy, positive predictive value and negative predictive value of AngioIMR versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-patient basis. [1 hour]

    Diagnostic accuracy, positive predictive value and negative predictive value of AngioIMR versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-patient basis.

  6. Diagnostic performance of AngioIMR in comparison to IMR on a per-vessel basis. [1 hour]

    Diagnostic performance includes sensitivity, specificity, accuracy, positive predictive value and negative predictive value.

  7. AUC and ROC of AngioIMR Versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-vessel basis and a per-patient basis. [1 hour]

    AUC and ROC of AngioIMR Versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-vessel basis and a per-patient basis.

  8. The consistency of AngioIMR Versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-vessel basis and a per-patient basis. [1 hour]

    The consistency of AngioIMR Versus wire-based IMR for demonstration of coronary microvascular dysfunction on a per-vessel basis and a per-patient basis.

  9. Diagnostic sensitivity and specificity of AngioQFA and QCA DS% versus wire-based FFR for demonstration of coronary ischemia. [1 hour]

    FFR≤0.80 is defined as "positive", FFR>0.80 is defined as "negative"; DS%≥50% is defined as "positive", DS%<50% is defined as "negative".

  10. Diagnostic accuracy of AngioQFA versus wire-based FFR for demonstration of coronary ischemia after PCI. [1 hour]

    Postoperative FFR≤0.89 was defined as "positive", FFR>0.89 is defined as "negative".

  11. The Pearson correlation coefficient and consistency of AngioQFA Versus wire-based FFR for demonstration of ischemia on a per-vessel basis after PCI. [1 hour]

    The Pearson correlation coefficient and consistency of AngioQFA Versus wire-based FFR for demonstration of ischemia on a per-vessel basis after PCI.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

  • General Inclusion Criteria:
  1. Age ≥18 years.

  2. Coronary angiography is required for patients with suspected or confirmed coronary artery disease.

  3. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

  • Angiographic Inclusion Criteria:
  1. Diameter stenosis of 30%-90% by visual estimate

  2. Reference vessel size ≥2 mm in stenotic segment by visual estimate

Exclusion Criteria:
Patients meeting any of the following criteria will be excluded:
  • General Exclusion Criteria:
  1. Subject has undergone CABG of the target vessel.

  2. Evidence of an acute myocardial infarction within one week prior to the intended procedure.

  3. Severe heart failure (NYHA≥III)

  4. Patients with other serious conditions not eligible for clinical trials, such as severe arrhythmia or tachycardia, sinus syndrome, asthma, severe chronic obstructive pulmonary disease.

  5. Serum creatinine level of >150µmol / L.

  6. Subject has known allergy to iodinated contrast agents, adenosine, or ATP.

  7. Pregnant or breastfeeding.

  8. Repeated enrollment.

  9. Any other factors that the researchers consider not suitable for diagnostic intervention or FFR and IMR detection, such as the target vessel has collateral circulation, coronary spasm, the target vessel plaque rupture resulting in myocardial infarction, or other reasons deemed unsuitable for inclusion.

  • Angiographic Exclusion Criteria:
  1. Myocardial bridge or coronary artery fistula on the study lesions.

  2. The target lesion ≥50% diameter stenosis in the left main coronary artery or ostial lesions less than 3 mm to the RCA.

  3. Low-quality angiography with poor contrast agent filling or inability to detect vascular boundaries due to various reasons, vascular overlap or severe distortion of the target vessel to fully expose the lesion location is not expected to be calculated.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
  • Renmin Hospital of Wuhan University
  • Yan'an Affiliated Hospital of Kunming Medical University
  • Sir Run Run Shaw Hospital
  • The Eighth Affiliated Hospital of Sun Yat-sen University
  • Jieyang People's Hospital

Investigators

  • Study Director: Hong Jiang, Renmin Hospital of Wuhan University
  • Principal Investigator: Qiang Xue, Yan'an Affiliated Hospital of Kunming Medical University
  • Principal Investigator: Guosheng Fu, Sir Run Run Shaw Hospital
  • Principal Investigator: Jianwen Liang, The Eighth Affiliated Hospital of Sun Yat-sen University
  • Principal Investigator: Qiang Wu, Jieyang People's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
ClinicalTrials.gov Identifier:
NCT06039748
Other Study ID Numbers:
  • The FAIR Study
First Posted:
Sep 15, 2023
Last Update Posted:
Sep 15, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 15, 2023